No abstract

WTPs. For a WTP of $270,000, the P(CE) for the no screen option was .482 with the TRI distributions and .535 with our revised distributions. ConClusions: In this case, despite the criticism of triangular distributions generally, CEA results were not appreciably different qualitatively or quantitatively with the change to more accepted distributional assumptions. For an intervention with an ICER closer to the CE threshold, the importance may be greater.

A821 addition, CRT was projected to be cost-effective, with incremental cost-effectiveness ratios ranging from MXN 375,458 (vs. CRZ) to MXN 610,125 (vs. PC). Deterministic and probabilistic sensitivity analyses demonstrated that results were robust across model inputs and assumptions. ConClusions: CRT was projected to result in the best health outcomes for PT/CN-EX ALK+ NSCLC patients compared to current treatment regimens in Mexico, while also being a cost-effective therapy.

The average length of hospitalizations per ICD ranged from 4.2 (stricture of artery) to 16.4 days (cardiac arrest), and the average cost per day of hospitalization varied from R$2.9 thousand (stroke) to R$9.4 thousand (CAD). These costs may still be underestimated, as study limitations include the lack of a standardized reporting process and ICD not being a mandatory information at the medical billing. ConClusions: Hospitalizations and procedures due to CVD heavily affect the private healthcare system, both economically and in occupation of hospital beds, tending to increase due to population ageing in Brazil. There is a significant unmet need for reducing risk factors and consequently CV events.

Objectives: This study aims to estimate the current and future burden of cardiovascular diseases (CVD) in Turkey, and quantify the impact of reducing modifiable risk factors. MethOds: A burden of disease model was used to forecast the burden of CVD in Turkey, and estimate the impact of reducing modifiable risk factors (tobacco use, hypertension, type 2 diabetes, obesity and physical inactivity) in the general Turkish population, in accordance with World Health Organization (WHO) targets. Another model estimated the impact of reducing LDL-cholesterol through increased access to effective treatment for two high risk populations: heterozygous familial hypercholesterolemia (HeFH) and secondary prevention (SP), with a focus on patients with LDL-cholesterol > 100 mg/dL. Inputs for the models included disease and risk factor prevalence, population forecast, CVD event rates, and treatment effectiveness, primarily derived from published literature. Direct costs to the public health care system and indirect costs from lost productivity due to premature mortality, hospitalizations, and early retirement were included, although the cost of programs and pharmacological interventions to reduce risk factors was not considered. Results: The prevalence of CVD is projected to increase to 5.4 million adults by 2035, while the economic burden, including both direct and indirect costs, would increase to US$5.7 billion. The value of reducing modifiable risk factors (except LDL-cholesterol) is estimated at US$9.2 billion over the forecast period. Reducing the prevalence of uncontrolled LDL-cholesterol through increased access to evolocumab could lead to savings of up to US$691.3 million for HeFH patients and up to US$8.1 billion for high-risk SP patients over the forecast period. cOnclusiOns: The burden of CVD is significant and growing. Efforts to achieve WHO risk factor targets and further lower LDL-cholesterol through increased access to effective treatment for high-risk patients are projected to greatly reduce the clinical, economic, and humanistic burden of cardiovascular disease in Turkey. PCV67 Modelling The Burden of CardioVasCular disease in Brazil and The iMPaCT of reduCing ModifiaBle risk faCTors